EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry

Simon Erridge iD, Ophilia Leung, Carl Holvey, Ross Coomber, Sushil Beri, Shaheen Khan, Mark W Weatherall, James J Rucker, Michael W Platt, Mikael H Sodergren

Neuropsychopharmacology Reports · 2023

DOI: 10.1002/npr2.12403 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neuropsychopharmacology Reports, 2023. Verfasst von Simon Erridge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Cannabis, Medical Marijuana, Hallucinogens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

While there is increasing evidence of the effects of cannabis‐based medicinal products (CBMPs) on health‐related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. This study aims to analyze changes in HRQoL in patients prescribed a homogenous selection of CBMPs.

Methods

Primary outcomes were changes in patient‐reported outcomes (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance was defined as p < 0.050.

Results

1378 patients prescribed Adven® CBMPs (Curaleaf International, Guernsey, UK) were included in the final analysis. 581 (42.16%) participants were current users of cannabis at baseline. 641 (46.51%), 235 (17.05%), and 502 (36.43%) patients were treated with oils, dried flowers, or a combination of the two, respectively. Improvements were found in all PROMs in each route of administration at 1, 3, 6, and 12 months from baseline ( p < 0.010). Those prescribed dried flower only or both oils and dried flower experienced greater improvements in GAD‐7, SQS, and EQ‐5D‐5L index values at 12 months ( p < 0.050). There was no difference in outcomes between those prescribed dried flower only or dried flower with oils ( p > 0.050). 3663 (265.82%) adverse events were reported by 297 (21.55%) patients.

Conclusion

There was an associated improvement in self‐reported anxiety, sleep quality, and HRQoL in patients treated with the CBMPs. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. However, these results must be interpreted with caution given the limitations of study design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabisMedical MarijuanaHallucinogensHumansQuality of LifeOilsUnited KingdomOutcome Assessment, Health Care

Stichwörter der Autor:innen

anxietycannabidiolcannabissleeptetrahydrocannabinol

Substanzen

Medical MarijuanaHallucinogensOils

Autor:innen und Institutionen

  • Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Sapphire Medical Clinics, London, UK.
  • St. George's Hospital NHS Trust, London, UK.
  • Guy's & St. Thomas' NHS Foundation Trust, London, UK.
  • Buckinghamshire Healthcare NHS Trust, Amersham, UK.
  • Department of Psychological Medicine, Kings College London, London, UK.

ORCID-Profile: Simon Erridge

Zitieren

APA

Erridge, S., Leung, O., Holvey, C., Coomber, R., Beri, S., Khan, S., Weatherall, M. W., Rucker, J. J., Platt, M. W., & Sodergren, M. H. (2023). An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12403

Vancouver

Erridge S, Leung O, Holvey C, Coomber R, Beri S, Khan S, et al. An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry. Neuropsychopharmacology Reports. 2023. doi:10.1002/npr2.12403

BibTeX
@article{Erridge2023,
  author = {Erridge, Simon and Leung, Ophilia and Holvey, Carl and Coomber, Ross and Beri, Sushil and Khan, Shaheen and Weatherall, Mark W and Rucker, James J and Platt, Michael W and Sodergren, Mikael H},
  title = {An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry},
  journal = {Neuropsychopharmacology Reports},
  year = {2023},
  doi = {10.1002/npr2.12403}
}
Kostenlos starten →